Replicel Life Sciences was granted patents addressing the use of RCT-01 fibroblast cell technology to treat chronically damaged tendons.
The granted patents were received in:
- China (Patent No. ZL201480011232.2)
- Europe (Patent No. 2956543)
- Russia (Patent No. 2678878)
Additionally, U.S. Patent No. 10272118 will be granted by the end of April 2019. These patents pertain to Replicel's non-bulbar dermal sheath cup cell technology and methods for the treatment of chronically damaged tendons.
This technology was the subject of successful Phase I clinical evaluation in chronic Achilles tendinopathy in a Canadian study. Replicel will pursue next-phase clinical testing and commercial launch in Japan while concurrently co-developing it in China with its partner, YOFOTO Health Co.
Source: RepliCel Life Sciences, Inc.